Document is current
Any future updates will be listed below
-
Authors
Thejer, Bashar M.
Adhikary, Partho P.
Kaur, Amandeep
Teakel, Sarah L.
Van Oosterum, Ashleigh
Seth, Ishith
Pajic, Marina
Hannan, Katherine M.
Pavy, Megan
Poh, Perlita
Jazayeri, Jalal A.
Zaw, Thiri
Pascovici, Dana
Ludescher, Marina
Pawlak, Michael
Cassano, Juan C.
Turnbull, Lynne
Jazayeri, Mitra
James, Alexander C.
Coorey, Craig P.
Roberts, Tara L.
Kinder, Simon J.
Hannan, Ross D.
Patrick, Ellis
Molloy, Mark P.
New, Elizabeth J.
Fehm, Tanja N.
Neubauer, Hans
Goldys, Ewa M.
Weston, Leslie A.
Cahill, Michael A.
-
Funding
Funding for this research was provided by:
Iraqi Cultural Attaché in Canberra (N/A)
Charles Sturt University (N/A)
University of Sydney (World Scholars Scholarship)
Australian Research Council (CE140100003)
Australian Research Council (DE120102687)
Ramaciotti Foundations (ES2012/0051)
Cancer Institute NSW (Future Research Leader Fellowship)
National Health and Medical Research Council (RD Wright Biomedical Career Development Fellowship)
Cancer Institute NSW (Career Development Fellowship)
- License Information
-
More Information
Article History
Received: 16 January 2020
Accepted: 4 March 2020
First Online: 3 April 2020
Ethics approval and consent to participate
: Mouse experiments were approved by The Australian National University Animal Experimentation Ethics Committee ethics protocol ANU A2017/16, and by Charles Sturt University Animal Care and Ethics Committee ethics protocol CSU A17046. ANU ethics approval and the provision agreement with the Australian Phenomics Facility at the Australian National University (ANU) (the provider of animals), included permission to use the animals in this study.
: Not applicable.
: M.A.C. is scientific advisor to and minor shareholder of Cognition Therapeutics, a company developing sigma-2 receptor ligands against Alzheimer’s disease. This work was performed independently of and without input from the company. The authors declare that they have no other competing interests.
